Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Emory University
- Target Recruit Count
- 226
- Registration Number
- NCT02408120
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Normal Versus Dual Wave Insulin Bolus for High-protein Food
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT02276859
- Locations
- 🇵🇱
Department of Pediatrics, Medical University of Warsaw, Poland, Warsaw, Poland
A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT02131246
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
- Conditions
- Interventions
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT02100475
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT02035371
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 501
- Registration Number
- NCT02034513
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Manati, Puerto Rico
A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT02033239
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 67
- Registration Number
- NCT02003677
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT01999322
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT01992588
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.